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Abstract
Purpose Stenting in intracranial atherosclerotic disease
(ICAD) is increasingly debated, due to issues of procedural
safety, technical efficacy, and in-stent recurrent stenoses
(ISR). In the present study, feasibility, safety, and efficacy
of angioplasty using a drug-eluting balloon (DEB) fol-
lowed by the implantation of a self-expanding stent
(Enterprise) were evaluated for the treatment of ICAD
lesions.
Methods Fifty-two patients (median age: 71 years; range:
54–86 years; male/female ratio 37:15) underwent stenting
of high-grade ICAD lesions between February 2010 and
November 2011 in a single center. Angioplasty using a
paclitaxel coated SeQuent Please (B. Braun, Germany) or
DIOR (Eurocor, Germany) coronary PTCA balloon, fol-
lowed by the implantation of a self-expanding stent
(Enterprise, Codman, USA) was performed in 54 lesions.
Angiographic and clinical follow-up was performed at 6
and 12 weeks, 6 and 12 months, and yearly thereafter.
Technical success rate, periprocedural complications,
occurrence of recurrent ischemic symptoms, and the
development of an ISR were analyzed.
Results Angioplasty using a DEB followed by stent
implantation was successfully performed in 44 (81 %)
cases. DEB insertion failed in 19 % of the cases and
angioplasty was finally performed using a conventional
PTCA balloon. The combined procedure related permanent
neurologic morbidity and mortality rate (stroke, ICH, and
subarachnoid hemorrhage) at 30 days and beyond was 5 %.
Angiographic and clinical follow-up were obtained in 33
(61 %) lesions in 32 patients. Recurrent stenosis was seen
in one (3 %) lesion.
Conclusion Angioplasty and stenting using a DEB is safe
and yields encouragingly low ISR rates. Further technical
developments to improve lesion accessibility are, never-
theless, mandatory.
Keywords Neurointerventions  Arterial intervention 
Angioplasty/angiogram
Introduction
Intracranial atherosclerotic disease (ICAD) is responsible
for at least 8–10 % of cerebral ischemic strokes [1].
Medical therapy alone does not provide sufficient protec-
tion against ischemic stroke in patients with symptomatic
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intracranial stenotic lesions. In the Warfarin–Aspirin
Symptomatic Intracranial Disease (WASID) study, the
2-year rate of ischemic stroke in patients with symptomatic
ICAD and on high-dose aspirin medication was 19.7 % [2].
The recently published data from the prematurely halted
SAMMPRIS trial, which evaluated whether intracranial
angioplasty combined with stenting using the Wingspan
system adds benefit to aggressive medical therapy alone for
preventing stroke in patients with ICAD, showed a 1-year
stroke probability rate of 12.2 % in the territory of the
affected artery despite aggressive medical-management
[3]. In the same trial, percutaneous angioplasty and stenting
of symptomatic high-grade intracranial stenoses using the
Wingspan stent was performed with a surprisingly high,
14.7 % 30-day stroke rate and a 20 % 1-year probability of
stroke in the territory of the affected vessel. Recurrent
strokes resulting from in-stent recurrent stenoses (ISR),
however, were not yet considered in this estimation,
although recurrence rates as high as 31 % have been
reported previously with the Wingspan stent [4, 5].
The use of balloon mounted drug-eluting coronary stents
in ICAD showed promising results with recurrence rates as
low as 3.9 %. These devices however proved to be too
rigid for intracranial application in patients with tortuous
supra-aortic and intracranial vasculature and resulted in
relatively high rates of failed treatment attempts between 4
and 14 % [6]. Angioplasty using a properly selected con-
ventional PTCA balloon followed by the implantation of a
self-expanding bare metal stent, on the other hand, can be
performed even in lesions of distal segments of intracranial
arteries in almost any anatomical situation, but at the cost
of the above-mentioned high ISR rates of 24–31 % [5, 7].
Recently, encouraging results have been published for
the reangioplasty of intracranial ISR lesions using a pac-
litaxel eluting PTCA balloon, which proved to be more
than fivefold effective in the prevention of ISR compared
with conventional balloons [8]. The purpose of the present
study was to evaluate the feasibility, procedural safety, and
stroke prevention efficacy of a modified angioplasty and
stenting protocol, using a paclitaxel-eluting PTCA balloon
for angioplasty, followed by the implantation of a self-
expanding neurovascular stent (Enterprise).
Methods
Patient Selection
The present series comprised 52 consecutive patients who
underwent elective endovascular treatment of 54 signifi-
cant (C50 %) intracranial atherosclerotic arterial stenoses
in the period from February 2010 to November 2011 in a
single institution by or under the supervision of the senior
author, according to identical principles of pre-, per-, and
postprocedural management.
Endovascular treatment by angioplasty with the paclit-
axel coated SeQuent Please (B. Braun, Berlin, Germany) or
Dior (Eurocor, Bonn, Germany) coronary PTCA balloon
followed by the implantation of the self-expanding Enter-
prise stent (Codman & Shurtleff, Raynham, MA) was
offered to patients with a symptomatic or progressive
intracranial stenotic lesion or if the affected vascular ter-
ritory had no sufficient collaterals (multivessel disease).
Endovascular treatment also was offered for lesions that
were discovered during the pretreatment angiography
during the endovascular treatment of a symptomatic intra-
or extracranial stenotic lesion. The above mentioned
lesions are considered to carry an increased risk of sub-
sequent cerebral ischemia [9, 10]. Failure of previous
medical therapy was not a compulsory indication criterion
for the endovascular treatment.
The treated lesions were located on the extra- and intradural
internal carotid artery (ICA), the middle cerebral artery
(MCA), the intradural vertebral artery (VA), or the basilar
artery (BA). Excessive atherosclerotic tortuosity and major
caliber difference of the target vessel proximal and distal to the
stenotic segment were considered as contraindications for the
use of the rather rigid drug-eluting angioplasty balloon.
All patients were explicitly informed and gave informed
consent to the off-label intracranial use of the coronary
drug-eluting balloon and the off-label use of the Enterprise
stent for the treatment of stenotic lesions, because this stent
is certified for intracranial use in the setting of stent-
assisted coiling of cerebral aneurysms. Further details on
the legal aspects on off-label use of medical devices within
the German jurisdiction are given elsewhere [6].
Procedures
Patients included in the study were examined by an inde-
pendent neurologist before and after the endovascular treat-
ment and were administered a dual platelet anti-aggregation
regime with a loading dose of 500 mg of acetylsalicylic acid
(ASA) and 600 mg of clopidogrel given at least 1 day before
the treatment, followed by 100 mg of ASA and 75 mg of
clopidogrel daily for at least 1 year, and 100 mg of ASA daily
thereafter. The endovascular procedures were performed
under general anesthesia using a 6F or 8F guiding catheter.
Intraprocedural medication included 5,000 U of intravenous
heparin, 500 mg of intravenous ASA, and 2 mg of intra-
arterial glycerintrinitrate through the guiding catheter for the
prevention of mechanically induced vasospasm.
Stenosis grade, length, and normal vessel diameter of
the target lesion were determined and the vessel distal to
the stenosis was catheterized with a SilverSpeed-14
(Covidien/ev3, Irvine, CA) or a Traxcess14 (Terumo
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Medical Corporation, Somerset, NJ) microguidewire under
roadmap guidance.
The diameter of the drug-eluting balloon (DEB) was
selected to correspond to approximately 80 % of the
diameter of the normal vessel. Predilatation with a smaller
diameter (1.0–1.5 mm) balloon (Ryujin Plus, Terumo
Medical Corporation, Somerset, NJ) was performed in
high-grade lesions to facilitate the advancement of the
more rigid DEB over the lesion. Balloons were slowly
inflated at nominal pressures (i.e., Ryujin Plus: 6 atm,
SeQuent Please: 7 atm, Dior: 6 atm) using a manometer,
and DEBs were left inflated for 60 s to allow for the
transition of the paclitaxel from the balloon surface into the
vessel wall. After deflation and withdrawal of the DEB, a
flushed 0.021 in. ID microcatheter (RapidTransit or
Prowler Select Plus, Codman & Shurtleff, Raynham, MA)
was inserted over the exchange wire. Following the
removal of the microguidewire an Enterprise stent
(Codman) with a nominal diameter of 4.5 mm and a length
of 14, 22, 28, or 37 mm was centered over the lesion and
deployed. During the first days after the procedure systolic
blood pressure was maintained strictly at B130 mmHg. All
patients underwent MRI and clinical assessment prior to
discharge. Angiographic follow-up and neurological
examination with emphasis on intermittent ischemic events
was performed at 6 weeks, 12 weeks, 6 months, and
12 months following the procedure and yearly thereafter.
Results
A total of 52 patients (median age: 71 years; age range:
54–86 years; male-to-female ratio: 37:15) with n = 54
intracranial atherosclerotic lesions were included in this
study. Lesion locations were as follows: ICA extradural
(n = 2, 4 %), ICA intradural (n = 5, 9 %), MCA (n = 13,
24 %), intradural VA (n = 18, 33 %), and BA (n = 16,
30 %). The distribution of the lesions within intradural and
extradural vessel segments was 52 (96 %) and 2 (4 %),
respectively.
Of the 54 lesions, 6 (11 %) were asymptomatic and were
originally identified on the preprocedural angiographic
images at the treatment of a symptomatic high-grade lesion
of another intracerebral artery, and 45 (83 %) were
symptomatic (TIA, stroke or silent infarcts in the supply
area of the affected vessel). There was one rapidly pro-
gressive lesion of the V4 segment of the left vertebral
artery found on the follow-up angiography following a
thrombectomy of the basilar artery with a lumen reduction
of 83 % (n = 1, 1.8 %). There was an extradural stenotic
lesion of the right ICA with a luminal reduction of 57 %,
detected during the treatment of a symptomatic high-grade
stenotic lesion of the right MCA (n = 1, 1.8 %). Finally,
there was a high-grade lesion in the V4 segment of the left
vertebral artery with complete occlusion of the right VA
and insufficient collateralization of the posterior circulation
through the hypoplastic posterior communicating arteries
(n = 1, 1.8 %).
Of the 45 symptomatic lesions, exact date of symptom
onset was available in 44 cases (97 %). Average number of
days between symptom onset and treatment was 63 ± 27
(standard error of mean); the shortest pretreatment period
was 0 days (i.e., treatment performed on the day of
symptoms onset) and the longest period was 1,130 days.
The severity of the stenoses was 50–69 % in 29 (54 %)
and[70 % in 25 (46 %) of the lesions. The average degree
of the target stenoses was determined as 69.4 ± 1 %
before and 30 ± 2 % after the treatment. In five cases
(9 %), residual stenoses from 56–62 % were seen on the
final postinterventional angiogram. A summary of lesion
characteristics is given in Table 1.
Predilatation using a smaller diameter (1.0–1.5 mm) con-
ventional PTCA balloon (Ryujin Plus, Terumo) was per-
formed in 13 cases (24 %). Angioplasty using the SeQuent
Please DEB was attempted in 51 (94 %) cases and was suc-
cessful in 39 cases, giving a 24 % failed-attempt rate. Suc-
cessful angioplasty with the Dior DEB could be performed in
five of six attempted cases, giving a 16 % percent failure rate.
Three of the six attempts using the Dior DEB were done as a
second attempt following the failure of the SeQuent Please
DEB. Overall, successful angioplasty using a DEB could be
performed in 44 (81 %) cases. In the remaining ten (19 %)
cases, difficult anatomy combined with the shaft thickness and
the rigidity of the DEB-tip precluded the insertion of the DEBs
Table 1 Lesion distribution
and characteristics
Lesion location 50–70 %/[70 % [n (%)] Asymptomatic/symptomatic/
multivessel disease [n (%)]
ICA extradural 2/0 (100/0) 1/0/1 (50/0/50)
ICA intradural 2/3 (40/60) 1/4/0 (20/80/0)
MCA 7/6 (54/46) 3/10/0 (23/77/0)
VA/V4 7/11 (40/60) 0/16/2 (0/90/10)
BA 11/5 (68/32) 1/15/0 (7/93/0)
Overall 29/26 (53/47) 6/46/3 (11/83/6)
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into the stenotic segment and the angioplasty in these lesion
was finally performed using a conventional PTCA balloon
(Ryujin Plus, Terumo).
Of the initial treatments, 42 (77 %) were completed with-
out any complication (Fig. 1). Major peri- and postprocedural
complications resulting in permanent neurological morbidity
and/or mortality beyond 30 days were encountered in three
cases (5 %); one patient died due to the consequences of the
complication (1.8 %). Minor procedure-related complica-
tions resulting in transient neurological symptoms with
complete resolution at 30 days postinterventionally occurred
in four (7 %) cases. In another four cases (7 %), clinically
silent DWI lesions, asymptomatic minor subarachnoidal
hemorrhage around the stented vessel segment, and asymp-
tomatic small petechiae in the basal ganglia were seen on the
routinely performed postprocedural CT or MRI scans.
Overall, the procedure-related neurological morbidity
and mortality at 30 days and beyond was 5 % (3/54). The
nature and clinical course of the complications are given in
detail in Table 2.
Subgrouping symptomatic lesions based on the occurrence
of adverse events revealed a trend of an inverse correlation
between the probability of procedure-related adverse events
and the time elapsed between symptom onset and treatment,
with average days-to-treatment values of 81 ± 37 days and
13 ± 5 days in the no complication and the adverse events
Fig. 1 Endovascular treatment and follow-up of a high-grade, long-
segment, vertebro-basilar stenotic lesion in a 67-year-old male patient
presenting with infarction in the pons (A). TOF angiogram revealed a
long, high-grade stenotic lesion in the middle and distal V4 segment
of the right VA and the proximal BA (B, connected arrows) and the
chronic occlusion of the distal V4 segment of the left VA
(B, arrowheads). The long, high-grade lesion on the right side
(C, connected arrows; the open arrow denotes the punctum maximum
of the lesion with a 70 % reduction in luminal diameter) has been
treated by angioplasty using a SeQuent Please DEB followed by the
implantation of a self-expanding Enterprise stent (D). The angio-
graphic follow-up 13 months after the procedure showed a com-
pletely patent right V4 segment without signs of neointimal
hyperplasia (E). The patient did not show any recurrent symptoms
during the follow-up period
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group, respectively, although analysis of variance failed to
show a statistical significance between the two groups
(ANOVA, P = 0.27). Further analysis of the relation between
treatment timing and adverse events rate showed that 6/12
(50 %) of all adverse events occurred in treatments performed
during the first week and 11/12 (92 %) of all adverse events
occurred in treatments performed during the first month after
symptoms onset.
Angiographic and clinical follow-up examinations
were obtained in 33 (61 %) of the lesions in 32 patients.
The average follow-up period was 8.9 months, and the
longest follow-up period was 16 months. Recurrent ste-
nosis defined as an in-stent stenotic lesion of more than
50 % lumen loss on the follow-up digital subtraction
angiography (DSA) series was seen in 1 of the 33 lesions
with DSA follow-up (3 %). The asymptomatic in-stent
recurrent stenotic lesion developed in the M1 segment of a
left MCA 3 months after the angioplasty with a DIOR DEB
and implantation of an Enterprise stent. Stent migration
was not observed in this series.
Table 2 Clinical and technical details of the periprocedural complications
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8 57 m TIA Intradural
VA
61 21 – – Small DWI lesions
in cerebellum
9 73 f Stroke Intradural
ICA
57 19 – – SAH around stented
ICA segment
10 66 m Silent
infarct
BA 75 20 – – Small DWI lesion in
pons
11 66 f Stroke Intradural
ICA





PTA percutaneous transluminal angioplasty, ICA internal carotid artery, MCA middle cerebral artery, VA vertebral artery, BA basilar artery, TIA
transient ischemic attack, BG basal ganglia, DWI diffusion weighted imaging, SAH subarachnoid hemorrhage
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Discussion
Although percutaneous angioplasty and stent implantation
for intracranial atherosclerotic stenotic disease is a widely
performed therapeutic option, procedural safety, technical
difficulties, and the high rate of recurrent in-stent lesions
remain a problem. The importance of these issues and the
impact of ICAD are well reflected in the public attention
and emerging professional debate, sparked by the recent
publication of the SAMMPRIS trial [3, 4]. The results in
the endovascular arm of this trial are surprisingly disap-
pointing: 6.7 % technical failure rate, 14.7 % stroke and
death rate within 30 days, with the majority (75 %) of
these strokes occurring within 1 day after the procedure as
procedural complication, and a projected 1-year stroke and
death rate of 20 % [3]. Moreover, as the current SAMM-
PRIS publication does not report the in-stent recurrence
(ISR) rates, the final results may be even worse, consid-
ering the reported high ISR rates of self-expanding bare
metal stents (24–31 %) [5, 7].
The recently published experience with the treatment of
209 intracranial stenotic lesions using conventional balloon
angioplasty followed by the implantation of a self-
expanding bare metal stent (Enterprise, Codman & Shurt-
leff) shows very good procedural feasibility with 100 %
technical success rate and acceptable procedural safety
with 0.9 % procedure-related morbidity and mortality at
30 days and beyond, however, with a rather discouraging
ISR rate of 24 % [7]. In another group of patients with 106
high-grade intracranial stenotic lesions treated with a drug-
eluting coronary stent (DES), a substantially lower recur-
rence rate of 3.8 % could be achieved with an acceptable
procedural complication rate of 0.9 %. Stent, balloon, and
catheter flexibility of the DES remain to be improved, as
7 % of the attempted interventions failed due to the rigidity
of the entire system [6].
Encouraging results with the treatment of intracranial
ISR lesions have been reported, using a paclitaxel-eluting
PTCA balloon (DEB) [8]. Thus, the rationale behind the
present series was to combine the technical ease and pro-
cedural safety of balloon angioplasty followed by stent
implantation with the beneficial effect of paclitaxel on the
ISR rate by performing the predilatation with a DEB.
The results are controversial. Although the ISR rate of
3 % after an average 8.9 months follow-up period is very
encouraging and the 5 % procedure related permanent
neurological morbidity and mortality rate can be regarded
as acceptable, the 19 % failed-attempt rate is certainly too
high. This is almost three times higher compared with the
drug-eluting coronary stents [6], although it should be
noted that the proportion of the attempted and technically
more challenging intradural lesions was much higher
(96 %) in the current than in the DES series (18 %).
The high failure rate can unequivocally be attributed to
the rigidity of the balloon shaft and to the stiffness of the
balloon tip. The drug-eluting PTCA balloons were origi-
nally developed for the coronary vasculature, where
maneuvering through elongated, difficult proximal access
vessels is rarely an issue. On the other hand, our previous
experience with the intracranial application of these bal-
loons in the redilatation of ISR lesions was much more
promising with only 6 % failure rate [8].
The physical properties of the two DEBs applied in this
study are slightly different. This results partly from the
differences in the balloons and partly from the different
principles of drug coating. SeQuent Please uses a coating
technology, where the bioavailability of paclitaxel is
enhanced through the addition of the modified contrast
medium molecule iopromide [11], whereas the DIOR
PTCA balloon catheter’s coating matrix consists of shellac,
a natural resin [12]. The number of cases in this study
(SeQuent Please: 52, DIOR: 6) does not allow any rea-
sonable conclusion regarding the superiority of one of the
above-mentioned coating technologies. Predilatation with a
more flexible, smaller diameter conventional balloon
facilitates the subsequently attempted advancement of
DEB through the stenotic vessel segment; however, it
makes the procedure more complicated and technically
demanding and adds an additional potential source of
complications. We believe that the eventual solution for the
access issues would be the development of a more flexible
DEB with hydrophilic coating, designed specifically for
intracranial vessels. The development of these balloons in
the near future would be of great importance, because long,
eccentric, high-grade, intracranial, stenotic lesions are
difficult to treat; the currently available drug-eluting cor-
onary stents are not suitable for these lesions due to their
stiffness, whereas the application of the sufficiently flexible
self-expanding, bare-metal stents results in poor recurrence
rates. The combination of the self-expanding stents with
the DEBs can be safe and efficient in treating this type of
lesions (Fig. 1.)
The observed trend of higher probability of periproce-
dural complications associated with the early treatment of
symptomatic lesions with 50 % of all adverse events
occurring when treatment was performed during the first
week and 92 % of all adverse events occurring when a
symptomatic lesion has been treated during the first month
after symptoms onset is in accordance with previous
observations regarding treatment timing [13, 14]. Possible
explanations for the higher periprocedural complication
rate observed following early revascularization of a
symptomatic, high-grade, intracranial, atherosclerotic
lesion include the vulnerability of perforator arteries orig-
inating from the stented segment (e.g., M1 segment of the
MCA or basilar trunk) and the concept of unstable and
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vulnerable plaque due to inflammatory processes. How-
ever, it cannot be excluded that those lesions with pre-
procedural complications also might be more prone to
repeat ischemic events when left untreated.
The procedure-related permanent neurological morbid-
ity and mortality rate of 5 % presented is much better than
the recently published 20 % periprocedural complication
rate in the endovascular arm of the SAMMPRIS study [3].
It has been long-known that patients treated in high-
enrollment endovascular centers have significantly lower
rates of periprocedural complications compared with low
enrollment centers with less than ten intracranial stenting
procedures performed yearly, with 5 % versus 29.3 %
complication rate in high- and low-volume centers,
respectively (14). Calculating the yearly number of intra-
cranial stenting procedures gives 1.9 treatment per center
per year in the endovascular arm of the SAMMPRIS study
[3] as opposed to 40.5 treatment per center per year in the
present study, which we believe is the main reason behind
the striking difference in the complication rates.
We are aware of the limitations of the present study.
First, a certain bias in patient selection was introduced,
because it was based on the experience and discretion of
the senior author. Second, data from a retrospective clinical
series are certainly more prone to inconsistencies compared
with those from a strictly regulated and externally moni-
tored prospective, randomized trial. Third, we did not
perform any direct comparison with other treatment
methods or devices, such as medical treatment alone,
stenting with bare-metal or drug-eluting coronary stents,
etc., therefore, the safety and efficacy of the method pre-
sented could be compared with historical data only. Fourth,
the presented number of cases is rather small compared
with larger, multicenter studies. Finally, clinical and
angiographic follow-up rate is limited without long-term
follow-up data at the present.
Conclusions
Endovascular treatment of atherosclerotic intracranial ste-
notic lesions by angioplasty using a drug-eluting balloon
followed by the implantation of a self-expanding stent is
feasible, relatively safe and results in low recurrence rates.
The physical properties of the drug-eluting balloons,
however, need to be improved substantially to achieve
adequate technical success rates, thereby making this
procedure applicable in patients with elongated supra-aor-
tic and intracranial vessels.
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